Merck Swaps Lead Attorney For Vioxx Appeal

Law360, New York (August 11, 2009, 10:49 PM EDT) -- Months after the U.S. Supreme Court agreed to hear Merck & Co. Inc.’s appeal of a decision that reinstated a securities class action alleging it concealed the health risks of its recalled painkiller Vioxx, the pharmaceutical giant has reportedly switched up its lead counsel, making its longtime attorney from Cravath Swaine & Moore LLP take a backseat.

Merck directed Evan R. Chesler, a presiding partner at Cravath, to step aside and let Williams & Connolly LLP partner Kannon K. Shanmugam head up the company’s case that...
To view the full article, register now.